Table 2 Enriched KEGG pathways derived from differentially expressed genes in monocytes in comparison to viremic patients versus long term non-progressors
Enriched pathway | Enrichment statistics |
|---|---|
Cell signaling | |
Chemokine signaling pathway | C=190;O=15;E=1.12;R=13.41;rawP=6.29e-13;adjP=2.64e-11 |
Toll-like receptor signaling pathway | C=101;O=11;E=0.59;R=18.49;rawP=2.39e-11;adjP=5.02e-10 |
NOD-like receptor signaling pathway | C=62;O=9;E=0.37;R=24.65;rawP=1.15e-10;adjP=1.61e-09 |
Neurotrophin signaling pathway | C=126;O=10;E=0.74;R=13.48;rawP=4.48e-09;adjP=4.70e-08 |
Cytokine-cytokine receptor interaction | C=267;O=13;E=1.57;R=8.27;rawP=8.49e-09;adjP=7.13e-08 |
T cell receptor signaling pathway | C=108;O=7;E=0.64;R=11.01;rawP=3.81e-06;adjP=1.78e-05 |
MAPK signaling pathway | C=269;O=10;E=1.58;R=6.31;rawP=5.15e-06;adjP=1.97e-05 |
Epithelial cell signaling in Helicobacter pylori infection | C=68;O=5;E=0.40;R=12.49;rawP=5.25e-05;adjP=0.0001 |
B cell receptor signaling pathway | C=75;O=5;E=0.44;R=11.32;rawP=8.41e-05;adjP=0.0002 |
VEGF signaling pathway | C=76;O=5;E=0.45;R=11.17;rawP=8.96e-05;adjP=0.0002 |
ErbB signaling pathway | C=87;O=4;E=0.51;R=7.81;rawP=0.0018;adjP=0.0023 |
Insulin signaling pathway | C=137;O=4;E=0.81;R=4.96;rawP=0.0090;adjP=0.0095 |
Wnt signaling pathway | C=151;O=4;E=0.89;R=4.50;rawP=0.0125;adjP=0.0128 |
Jak-STAT signaling pathway | C=155;O=4;E=0.91;R=4.38;rawP=0.0136;adjP=0.0136 |
Cell cycle and apoptosis | |
Lysosome | C=117;O=7;E=0.69;R=10.16;rawP=6.49e-06;adjP=2.27e-05 |
Apoptosis | C=88;O=6;E=0.52;R=11.58;rawP=1.43e-05;adjP=4.62e-05 |
Cell cycle | C=128;O=4;E=0.75;R=5.31;rawP=0.0071;adjP=0.0081 |
Cytoskeleton and cell migration | |
Leukocyte transendothelial migration | C=118;O=5;E=0.69;R=7.20;rawP=0.0007;adjP=0.0012 |
Regulation of actin cytoskeleton | C=216;O=6;E=1.27;R=4.72;rawP=0.0019;adjP=0.0023 |
Focal adhesion | C=201;O=5;E=1.18;R=4.22;rawP=0.0070;adjP=0.0081 |
Phagocytosis | |
Endocytosis | C=187;O=6;E=1.10;R=5.45;rawP=0.0009;adjP=0.0014 |
Fc gamma R-mediated phagocytosis | C=97;O=4;E=0.57;R=7.00;rawP=0.0027;adjP=0.0032 |
Natural killer cell mediated cytotoxicity | C=137;O=4;E=0.81;R=4.96;rawP=0.0090;adjP=0.0095 |
Metabolism | |
Glycolysis/Gluconeogenesis | C=62;O=7;E=0.37;R=19.17;rawP=8.47e-08;adjP=5.93e-07 |
Metabolic pathways | C=1104;O=18;E=6.50;R=2.77;rawP=0.0001;adjP=0.0002 |
Oxidative phosphorylation | C=135;O=4;E=0.80;R=5.03;rawP=0.0085;adjP=0.0094 |
Miscellaneous | |
Prion diseases | C=35;O=5;E=0.21;R=24.26;rawP=1.92e-06;adjP=1.01e-05 |
Bladder cancer | C=42;O=5;E=0.25;R=20.22;rawP=4.86e-06;adjP=1.97e-05 |
Long-term depression | C=70;O=5;E=0.41;R=12.13;rawP=6.04e-05;adjP=0.0002 |
Endometrial cancer | C=52;O=4;E=0.31;R=13.06;rawP=0.0003;adjP=0.0006 |
Oocyte meiosis | C=114;O=5;E=0.67;R=7.45;rawP=0.0006;adjP=0.0010 |
Glioma | C=65;O=4;E=0.38;R=10.45;rawP=0.0006;adjP=0.0010 |
Alzheimer's disease | C=169;O=6;E=1.00;R=6.03;rawP=0.0005;adjP=0.0010 |
Melanoma | C=71;O=4;E=0.42;R=9.57;rawP=0.0008;adjP=0.0013 |
Axon guidance | C=129;O=5;E=0.76;R=6.58;rawP=0.0010;adjP=0.0015 |
Tight junction | C=134;O=5;E=0.79;R=6.34;rawP=0.0012;adjP=0.0017 |